Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35240075

Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Haematol
Publication date
2022 Mar
First author
Kersting S

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Haematol. 2022 Mar;9(3):e169-e171. doi: 10.1016/S2352-3026(22)00044-8.
    note
    Source null
    related pmid
    35240069
    relationship
    Comment in

Authors and identifiers

  1. name
    Kersting S
    type
    Author
  2. name
    Dubois J
    type
    Author
  3. name
    Nasserinejad K
    type
    Author
  4. name
    Dobber JA
    type
    Author
  5. name
    Mellink C
    type
    Author
  6. name
    van der Kevie-Kersemaekers AF
    type
    Author
  7. name
    Evers LM
    type
    Author
  8. name
    de Boer F
    type
    Author
  9. name
    Koene HR
    type
    Author
  10. name
    Schreurs J
    type
    Author
  11. name
    van der Klift M
    type
    Author
  12. name
    Velders GA
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Kersting S
    type
    Author
  2. name
    Dubois J
    type
    Author
  3. name
    Nasserinejad K
    type
    Author
  4. name
    Dobber JA
    type
    Author
  5. name
    Mellink C
    type
    Author
  6. name
    van der Kevie-Kersemaekers AF
    type
    Author
  7. name
    Evers LM
    type
    Author
  8. name
    de Boer F
    type
    Author
  9. name
    Koene HR
    type
    Author
  10. name
    Schreurs J
    type
    Author
  11. name
    van der Klift M
    type
    Author
  12. name
    Velders GA
    type
    Author
bibliography ids
  1. nci-bib-3fe0c9f22da0c88d8b37e8e5
book metadata
content sha256
33d2d8d1d67b23e6a7e76effa40624c039a9a2e7827d57fd68443271c989be2a
document type
citation
dois
  1. 10.1016/S2352-3026(22)00034-5
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:35240075
immutable id
pubmed:35240075@33d2d8d1d67b23e6a7e76effa40624c039a9a2e7827d57fd68443271c989be2a
journal
abbreviation
Lancet Haematol
issn electronic
2352-3026
issn print
Source null
issue
3
name
The Lancet. Haematology
nlm unique id
101643584
pages
e190-e199
volume
9
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Haematol. 2022 Mar;9(3):e169-e171. doi: 10.1016/S2352-3026(22)00044-8.
    note
    Source null
    related pmid
    35240069
    relationship
    Comment in
outcomes validated
false
pmid
35240075
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
e7564e58f880806989921b9504b65018581bad427ee60d42ef68e13ffc04a6a3
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 Mar
precision
month
year
2022
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35240075/
title
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.

Preserved source evidence · Not medical advice